{"id":"monoclonal-antibody-ca2","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:06:13.475419","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"cA2 is a monoclonal antibody that selectively binds to the CD19 protein on the surface of B cells, marking them for destruction by the immune system. This mechanism of action is specific to B cell malignancies and autoimmune diseases where B cells are overactive.","oneSentence":"cA2 targets the CD19 protein on B cells to induce their destruction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:08.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell non-Hodgkin lymphoma"},{"name":"Relapsed or refractory follicular lymphoma"}]},"_fixedFields":["pubmed(22)"],"trialDetails":[{"nctId":"NCT07495644","phase":"","title":"Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03-01","conditions":"Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)","enrollment":95},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT03596645","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-29","conditions":"Colitis, Ulcerative","enrollment":84},{"nctId":"NCT05043870","phase":"PHASE4","title":"Combined Immunosuppression for Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-10-10","conditions":"Crohn Disease, Infliximab, Immunosuppression","enrollment":128},{"nctId":"NCT04372108","phase":"","title":"A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2021-06-24","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":1056},{"nctId":"NCT03819296","phase":"PHASE1","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-21","conditions":"Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8","enrollment":800},{"nctId":"NCT04835506","phase":"PHASE4","title":"Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2021-11-01","conditions":"Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":124},{"nctId":"NCT04438382","phase":"PHASE2","title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-01-07","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis","enrollment":1},{"nctId":"NCT07417696","phase":"PHASE4","title":"Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Chinese Medical Association","startDate":"2026-04-01","conditions":"Crohn's Disease","enrollment":400},{"nctId":"NCT07415473","phase":"PHASE4","title":"Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Chinese Medical Association","startDate":"2026-04-01","conditions":"Crohn's Diseases","enrollment":400},{"nctId":"NCT07177209","phase":"","title":"Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-02-27","conditions":"Ulcerative Colitis","enrollment":4000},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT04305145","phase":"PHASE2","title":"Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-08-31","conditions":"Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III","enrollment":42},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT01917721","phase":"PHASE2","title":"Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hawaii Pacific Health","startDate":"2013-10","conditions":"Kawasaki Disease, Coronary Aneurysm","enrollment":50},{"nctId":"NCT05034536","phase":"PHASE2","title":"PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-07","conditions":"Metastatic Melanoma","enrollment":36},{"nctId":"NCT00691028","phase":"PHASE3","title":"Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2005-09","conditions":"Rheumatoid Arthritis","enrollment":327},{"nctId":"NCT01580670","phase":"PHASE3","title":"Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-03","conditions":"Pediatric Crohn's Disease","enrollment":14},{"nctId":"NCT00805766","phase":"PHASE3","title":"Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-12","conditions":"Crohn's Disease","enrollment":39},{"nctId":"NCT03885037","phase":"","title":"Infliximab Biosimilar for Intravenous Drip Infusion 100 mg \"Pfizer\" Drug Use Investigation (Rheumatoid Arthritis)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-03-20","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT06646016","phase":"PHASE2","title":"EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis","status":"WITHDRAWN","sponsor":"Therakos LLC","startDate":"2025-12-15","conditions":"Immune-related Colitis","enrollment":""},{"nctId":"NCT07297069","phase":"PHASE2","title":"Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial","status":"NOT_YET_RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2026-01-01","conditions":"Acute Severe Ulcerative Colitis","enrollment":60},{"nctId":"NCT04407247","phase":"PHASE1, PHASE2","title":"Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-09","conditions":"Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm","enrollment":47},{"nctId":"NCT07263477","phase":"","title":"A Study on the Relationship of Interleukin-7 Receptor Gene Polymorphisms With the Risk of Crohn's Disease Onset and the Efficacy of Infliximab","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease (CD)","enrollment":900},{"nctId":"NCT07257068","phase":"NA","title":"Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-04-14","conditions":"Checkpoint Inhibitor, Pilot Study, Diabetes Melletus","enrollment":14},{"nctId":"NCT04898231","phase":"PHASE2, PHASE3","title":"MIS-C Comparative Effectiveness Study","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-12-22","conditions":"Multisystem Inflammatory Syndrome-Children","enrollment":73},{"nctId":"NCT05781152","phase":"PHASE4","title":"Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease","status":"RECRUITING","sponsor":"Connecticut Children's Medical Center","startDate":"2023-06-10","conditions":"Crohn Disease","enrollment":900},{"nctId":"NCT07176754","phase":"NA","title":"TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-10-01","conditions":"Cardiac Arrest (CA), Post Cardiac Arrest Syndrome","enrollment":208},{"nctId":"NCT03684278","phase":"PHASE2","title":"Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2019-05-01","conditions":"Acute Pancreatitis","enrollment":290},{"nctId":"NCT07149441","phase":"NA","title":"Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2025-08-01","conditions":"Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis), Fecal Microbiota Transplantation","enrollment":94},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT02638701","phase":"PHASE1, PHASE2","title":"Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-01","conditions":"Aneurysm, Stroke, Vasculitis","enrollment":8},{"nctId":"NCT00463580","phase":"PHASE4","title":"A Study of Infliximab for Treatment Resistant Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-12","conditions":"Depression","enrollment":60},{"nctId":"NCT03679546","phase":"PHASE4","title":"EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2019-01-04","conditions":"Ulcerative Colitis","enrollment":151},{"nctId":"NCT03885089","phase":"","title":"Infliximab Biosimilar for Intravenous Drip Infusion 100 mg \"Pfizer\" Drug Use Investigation (Psoriasis)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-10-21","conditions":"Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis","enrollment":10},{"nctId":"NCT05168475","phase":"PHASE2","title":"Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-07-14","conditions":"Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome","enrollment":22},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT03011268","phase":"NA","title":"Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?","status":"COMPLETED","sponsor":"Helse Møre og Romsdal HF","startDate":"2017-06-09","conditions":"Colitis,Ulcerative","enrollment":174},{"nctId":"NCT05906576","phase":"PHASE4","title":"Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients","status":"RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2023-09-21","conditions":"Crohn Disease","enrollment":30},{"nctId":"NCT03765450","phase":"","title":"Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2018-12-21","conditions":"Ulcerative Colitis","enrollment":18},{"nctId":"NCT06453317","phase":"PHASE2","title":"Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2025-02-17","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":172},{"nctId":"NCT03681652","phase":"","title":"Post-Operative Crohn's Disease Outcome in Children","status":"RECRUITING","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2019-02-11","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT06136546","phase":"PHASE2","title":"Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-01-23","conditions":"Depressive Disorder, Major, Inflammation","enrollment":100},{"nctId":"NCT04312659","phase":"","title":"A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease","status":"COMPLETED","sponsor":"Johnson & Johnson (China) Investment Ltd.","startDate":"2020-07-15","conditions":"Crohn Disease","enrollment":38},{"nctId":"NCT03884439","phase":"","title":"Infliximab Biosimilar \"Pfizer\" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-03-18","conditions":"Crohn's Disease, Ulcerative Colitis","enrollment":428},{"nctId":"NCT03885713","phase":"PHASE4","title":"Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2019-09-10","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":180},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT06758024","phase":"NA","title":"PROactive and Early Infliximab Monitoring and OPTimization in Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2025-01-24","conditions":"Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)","enrollment":72},{"nctId":"NCT03937609","phase":"PHASE4","title":"TITRATE (inducTIon for acuTe ulceRATivE Colitis)","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-09-04","conditions":"Colitis, Ulcerative","enrollment":50},{"nctId":"NCT02566889","phase":"PHASE4","title":"An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease","status":"TERMINATED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-04","conditions":"Inflammatory Bowel Diseases","enrollment":53},{"nctId":"NCT01804166","phase":"PHASE4","title":"A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-03-21","conditions":"Hepatosplenic T-Cell Lymphoma","enrollment":1},{"nctId":"NCT05660746","phase":"PHASE2, PHASE3","title":"Precise Infliximab Exposure and Pharmacodynamic Control","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-07-01","conditions":"Crohn Disease","enrollment":180},{"nctId":"NCT06786507","phase":"","title":"A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Helwan University","startDate":"2025-05-15","conditions":"Ulcerative Colitis (UC)","enrollment":100},{"nctId":"NCT04646187","phase":"PHASE4","title":"De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Center Groningen","startDate":"2021-03-11","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative","enrollment":148},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT05169593","phase":"PHASE4","title":"Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-09-08","conditions":"Crohn Disease","enrollment":292},{"nctId":"NCT04982172","phase":"PHASE4","title":"Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-02-08","conditions":"Inflammatory Bowel Diseases","enrollment":80},{"nctId":"NCT01706692","phase":"","title":"Swiss Dermatology Network of Targeted Therapies (SDNTT)","status":"RECRUITING","sponsor":"Swiss Dermatology Network for Targeted Therapies","startDate":"2011-02","conditions":"Psoriasis","enrollment":1121},{"nctId":"NCT06269185","phase":"","title":"Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2024-03-06","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":271},{"nctId":"NCT02770040","phase":"PHASE4","title":"Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Austin Health","startDate":"2016-07-18","conditions":"Ulcerative Colitis","enrollment":138},{"nctId":"NCT06614387","phase":"PHASE3","title":"Vedolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab","status":"NOT_YET_RECRUITING","sponsor":"JAROSLAW KIERKUS","startDate":"2024-10-01","conditions":"Ulcerative Colitis","enrollment":60},{"nctId":"NCT05552287","phase":"PHASE4","title":"Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2023-08-02","conditions":"Crohn Disease, Child, Only, Biologic; Inadequate","enrollment":50},{"nctId":"NCT05340764","phase":"PHASE4","title":"Safety of Reduced Infliximab Infusion Time","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-08-01","conditions":"Inflammatory Bowel Diseases","enrollment":96},{"nctId":"NCT02251041","phase":"PHASE2","title":"Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-09","conditions":"Reperfusion Injury","enrollment":143},{"nctId":"NCT05180994","phase":"PHASE1, PHASE2","title":"Topical Infliximab in Eyes With Penetrating Keratoplasty","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2022-05-01","conditions":"Glaucoma Following Surgery","enrollment":50},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT06113913","phase":"PHASE4","title":"Subcutaneous Infliximab After A Previous Intravenous Dose Optimization","status":"RECRUITING","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2024-04-09","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":275},{"nctId":"NCT04999241","phase":"PHASE4","title":"Combined Application of EEN in the Induction of Remission in PUC","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-03-01","conditions":"Exclusive Enteral Nutrition, Ulcerative Colitis, Children","enrollment":40},{"nctId":"NCT06033469","phase":"","title":"Therapeutic Monitoring of Infliximab and Adalimumab","status":"UNKNOWN","sponsor":"IRCCS Burlo Garofolo","startDate":"2018-03-15","conditions":"Inflammatory Bowel Diseases","enrollment":100},{"nctId":"NCT06064864","phase":"NA","title":"Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2023-10-09","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT05823532","phase":"PHASE4","title":"Anti-Inflammatory Challenge in Schizophrenia","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-04-18","conditions":"Schizophrenia","enrollment":20},{"nctId":"NCT01965132","phase":"","title":"Korean College of Rheumatology Biologics and Targeted Therapy Registry","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2012-12-01","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":10000},{"nctId":"NCT05375942","phase":"","title":"This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-11-11","conditions":"Arthritis, Rheumatoid","enrollment":255},{"nctId":"NCT05291039","phase":"NA","title":"Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2022-01-01","conditions":"Inflammatory Bowel Diseases","enrollment":56},{"nctId":"NCT02517684","phase":"PHASE4","title":"Top-down Infliximab Study in Kids With Crohn's Disease","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2015-04","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT01793519","phase":"PHASE4","title":"Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Georgetown University","startDate":"2013-01","conditions":"Rheumatoid Arthritis","enrollment":290},{"nctId":"NCT04999228","phase":"PHASE4","title":"Top Down Versus Step up in Pediatric Ulcerative Colitis","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2021-11-01","conditions":"Ulcerative Colitis, Infliximab, Children","enrollment":40},{"nctId":"NCT02987686","phase":"PHASE1","title":"Topical Infliximab for Sterile Corneal Melt","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2017-09-06","conditions":"Sterile Corneal Melt","enrollment":12},{"nctId":"NCT03704610","phase":"PHASE3","title":"Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-03-28","conditions":"Extrathoracic Sarcoidosis","enrollment":31},{"nctId":"NCT04131504","phase":"","title":"Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-10-16","conditions":"Crohn's Disease, IBD","enrollment":239},{"nctId":"NCT04891991","phase":"PHASE2","title":"Intravitreal Infliximab for Proliferative Vitreoretinopathy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-11-26","conditions":"Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy, Retinal Detachment","enrollment":66},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT05702879","phase":"","title":"Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success","status":"UNKNOWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-09-06","conditions":"Ulcerative Colitis","enrollment":240},{"nctId":"NCT05205603","phase":"PHASE4","title":"Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2022-01-15","conditions":"Ulcerative Colitis, Efficacy, Self, Biologics","enrollment":438},{"nctId":"NCT05663268","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Services Institute of Medical Sciences, Pakistan","startDate":"2022-10-01","conditions":"Hidradenitis Suppurativa","enrollment":37},{"nctId":"NCT02332356","phase":"PHASE3","title":"Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease","status":"UNKNOWN","sponsor":"Tokyo Medical and Dental University","startDate":"2014-09","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT03004443","phase":"PHASE4","title":"Inflammation-Induced CNS Glutamate Changes in Depression","status":"TERMINATED","sponsor":"Emory University","startDate":"2017-05-15","conditions":"Depression","enrollment":22},{"nctId":"NCT03945019","phase":"PHASE3","title":"CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-10-28","conditions":"Crohn's Disease","enrollment":396},{"nctId":"NCT04330690","phase":"PHASE3","title":"Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2020-03-18","conditions":"COVID-19","enrollment":2900},{"nctId":"NCT04205643","phase":"PHASE3","title":"CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-09-01","conditions":"Ulcerative Colitis","enrollment":548},{"nctId":"NCT04593940","phase":"PHASE3","title":"Immune Modulators for Treating COVID-19","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2020-10-15","conditions":"Covid19","enrollment":1971},{"nctId":"NCT03445624","phase":"","title":"Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-07-01","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT05947669","phase":"PHASE3","title":"Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2023-08-22","conditions":"Colitis","enrollment":195},{"nctId":"NCT05280405","phase":"PHASE4","title":"Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study","status":"UNKNOWN","sponsor":"IRCCS Burlo Garofolo","startDate":"2022-03-09","conditions":"Inflammatory Bowel Diseases","enrollment":86},{"nctId":"NCT00686595","phase":"PHASE4","title":"A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-01","conditions":"Psoriasis","enrollment":48},{"nctId":"NCT04922827","phase":"PHASE2","title":"Infliximab in the Treatment of Patients With Severe COVID-19 Disease","status":"COMPLETED","sponsor":"Jena University Hospital","startDate":"2021-06-18","conditions":"COVID-19","enrollment":9},{"nctId":"NCT05931458","phase":"NA","title":"AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Federico II University","startDate":"2023-07-01","conditions":"Ulcerative Colitis","enrollment":94}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"recentPublications":[{"date":"2006 May 15","pmid":"16707608","title":"Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"date":"2004","pmid":"14974022","title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.","journal":"The Cochrane database of systematic reviews"},{"date":"2001","pmid":"11673664","title":"A chimeric anti-TNFalpha monoclonal antibody (cA2) in vivo removes TNFalpha-producing cells in Crohn's disease.","journal":"Human antibodies"},{"date":"2000 Feb","pmid":"10685789","title":"In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2.","journal":"The Journal of rheumatology"},{"date":"2000 Jan","pmid":"10643698","title":"Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.","journal":"Arthritis and rheumatism"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"monoclonal antibody cA2","genericName":"monoclonal antibody cA2","companyName":"FDA Office of Orphan Products Development","companyId":"fda-office-of-orphan-products-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"cA2 targets the CD19 protein on B cells to induce their destruction. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Relapsed or refractory follicular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}